Ollin Biosciences to Participate in Two Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.

Piper Sandler Biopharma Symposium

1x1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA

UBS Private Biotech Summit

1x1 Meetings: Monday, May 18, 2026
Location: New York, NY

About Ollin Biosciences

Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408503553/en/

Media & Investors:
Katie Engleman
1AB
[email protected]

Source: Ollin Biosciences, Inc.

You May Also Be Interested In

• NuScale Power and MillenniTEK Advance Manufacturing Technology for First-of-a-Kind Reactor Safety Component
• SB Energy Announces Public Filing of Registration Statement for Proposed Initial Public Offering
• MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration